Fulcrum Therapeutics is a clinical-stage biopharma company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need.
We launched Fulcrum Therapeutics with a vision to develop small molecules to improve the lives of patients with genetically defined rare diseases.
Our approach to drug discovery led to the identification of small molecules for the potential treatment of FSHD and hemoglobinopathies such as Sickle Cell Disease. We take great pride in being purposeful patient partners who do this work, not just for patients, but with patients. We have a culture of trust and transparency which enables our employees to focus on our mission and the science behind it.